Inspire360’s Q1 2026 report tracks how fitness clubs are responding to rising GLP-1 use, highlighting new partnerships, policy changes and trainer education gaps.

A new aytm survey of 1,000 U.S. adults finds weight loss goals shifting toward health, diet changes, and GLP-1 medications rather than appearance.

UFC GYM has partnered with NexGen MD Scientific to launch in-club longevity clinics offering GLP-1 and peptide therapies, marking its expansion into integrated fitness and telehealth services.

Planet Fitness reports strong 2025 earnings with 6.7% same club sales growth and 1.1 million net new members, while positioning itself to capture demand from GLP-1 users through strength training, recovery amenities, and new partnerships.

A new ResearchAndMarkets report projects the GLP-1 agonists market to reach USD 170.75 billion by 2033, driven by rising obesity treatment demand and staggered patent expirations across global markets.

Noom expands into longevity with a GLP-1 microdosing program that combines medication, behavior change coaching, and at-home biomarker testing to support early intervention and long-term metabolic health.

Weight Watchers launches a fully integrated GLP-1 platform combining prescriptions, personalized nutrition, coaching, community, and new digital tools to support sustainable weight loss.

New Shed survey shows rising extreme weight loss behaviors, low industry trust, and shifting GLP 1 influence as Americans search for sustainable health.

WHO has endorsed GLP1 therapies in its first obesity treatment guideline as global cases exceed one billion, highlighting the role of medication alongside nutrition, physical activity and long term care.

Medicare will begin covering GLP-1 medications in 2026 under a new Trump Administration policy. The Health & Fitness Association welcomes the move but urges policymakers to integrate exercise and lifestyle programs for lasting health benefits.

The global anti-obesity drugs market is projected to grow from 19.6 billion dollars in 2025 to 104.9 billion dollars by 2035, driven by rising obesity rates and new drug innovations.

A new NASM survey of nearly 500 fitness professionals reveals how weight loss medications are reshaping the industry, shifting the focus from calorie burn to muscle preservation, strength, and long-term health.

FuturHealth now offers Apple Fitness+ at no cost for GLP-1 weight loss members, providing access to thousands of workouts and meditations to support sustainable results.

Novo Nordisk lowers 2025 outlook despite strong GLP-1 sales growth. What shifting obesity drug trends mean for the fitness industry.

Hims & Hers closed Q2 2025 with $544.8M in revenue up 73% year-over-year net income of $42.5M, and 2.44M subscribers. The company reaffirmed its full-year outlook.

One in three Canadian adults are now classified as obese, according to new data from the Canadian Medical Association Journal. The study reveals a post-pandemic acceleration in obesity rates, raising important considerations for the fitness industry as it adapts to shifting public health trends and the rise of GLP-1 use.

Hims & Hers enters Canadian market with a digital weight loss program leveraging generic semaglutide, signaling increased competition and accessibility in the growing GLP-1 and obesity treatment sector.

WeightWatchers expands its partnership with Novo Nordisk to improve access to FDA-approved Wegovy for weight loss. The collaboration includes a limited-time price of $299, integrated pharmacy fulfillment, and a commitment to real-world research combining GLP-1 treatment with lifestyle support.

ISSA launches a GLP-1 Weight Loss Support Training course to help fitness professionals safely guide clients using medications like Ozempic and Wegovy, addressing physical, emotional, and behavioral changes.

A new claims analysis by Aon found that GLP-1 users experienced a 44 percent reduction in cardiac hospitalizations and slower medical cost growth compared to matched control groups.